New Delhi: For thousands of Indians living with haemophilia, the daily fear of a sudden bleed could soon get a lot easier to manage. Sanofi Healthcare announced on Wednesday that it has received marketing authorisation from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for Qfitlia, a therapy that prevents bleeding with as few as six injections a year.
The approval covers adults and adolescents aged 12 years and older with haemophilia A or B, and works for patients with or without factor VIII or IX inhibitors. For a country where most haemophilia care still means rushing to the hospital after a bleed has already started, doctors say this could mark a real shift from reactive treatment to prevention.
Why this approval matters for India
Haemophilia is a rare, lifelong bleeding disorder in which the blood’s ability to clot is severely impaired. Patients can suffer spontaneous bleeds, particularly into joints, that cause permanent damage and disability over time. India has an estimated 28,900 registered people living with haemophilia, according to Sanofi India’s statement, and a large share of those receiving treatment are still on on-demand therapy, meaning they treat bleeds only after they occur.
That reality shapes daily life: patients live in constant anticipation of the next joint bleed and the next hospital visit, while prophylaxis has stayed out of reach for most because of cost, infrastructure, and awareness gaps.
“Qfitlia, with its unique ability to protect both those living with Haemophilia A and Haemophilia B (with or without inhibitors) with as few as six injections a year, has the potential to significantly expand access to prophylaxis in India,” said Parwas Mahajan, Business Head, Rare Diseases, Sanofi (India).
How Qfitlia works
Qfitlia’s active ingredient is fitusiran, and it takes a different route from conventional factor replacement therapies. It uses RNA interference to reduce antithrombin, a protein in the blood that limits clotting. By lowering this natural brake on the clotting process, the therapy helps the blood clot more effectively, reducing the frequency of bleeding episodes.
Some key features of the treatment:
- Dosing: As few as six injections a year, depending on the prescribed schedule, far less frequent than standard factor infusions that often run multiple times a week.
- Route: Given as a subcutaneous injection, meaning it goes just under the skin rather than into a vein.
- Coverage: Works for haemophilia A and B, including patients who have developed inhibitors that make standard factor treatments less effective.
- Purpose: Routine prophylaxis to prevent or reduce bleeding episodes, not a cure for the underlying disorder.
What the clinical trials showed
The CDSCO approval is based on data from the ATLAS phase 3 clinical development programme. According to the company’s statement, the trials showed clinically meaningful protection against bleeding across patients. Phase 3 trials are the final large-scale stage before regulatory approval, and regulators only clear a drug when the benefit-risk balance is convincingly established.
The hurdles between approval and patients
Regulatory clearance is a milestone, but it does not automatically put the therapy into patients’ hands. Three practical questions will decide how fast Qfitlia reaches people who need it:
- Pricing: Sanofi has not disclosed the India pricing yet. Innovative rare-disease therapies are typically expensive, and affordability will be the single biggest factor in uptake.
- Specialist access: Starting and monitoring a new prophylaxis regimen needs haematologists and treatment centres, which are concentrated in big cities. Patients in smaller towns may still struggle to access it.
- Awareness: Identifying the right candidates among the 28,900 registered patients, and reaching the many who may not be diagnosed or registered at all, will require outreach to doctors and patient groups.
Patient advocates have long argued that closing India’s haemophilia prophylaxis gap needs coordinated effort across drug companies, hospitals, and support systems. This approval creates that opportunity, but the infrastructure questions around cost and access remain open.
What should patients do now
If you or a family member lives with haemophilia, do not change anything about your current treatment on your own. Talk to your treating haematologist about whether a preventive regimen is right for your type of haemophilia and medical history.
FAQs
What is Qfitlia?
Qfitlia (fitusiran) is a Sanofi therapy for routine prophylaxis to prevent or reduce bleeding episodes in people with haemophilia A or B, approved by CDSCO for patients aged 12 years and older.
How often is Qfitlia given?
The regimen can involve as few as six injections a year, administered subcutaneously, far less frequent than traditional factor replacement schedules.
Does it work for patients with inhibitors?
Yes. The approval covers patients with or without factor VIII or IX inhibitors, which is significant because inhibitors make conventional treatments less effective.
Is Qfitlia a cure for haemophilia?
No. It is a preventive therapy that reduces bleeding episodes; it does not cure the underlying genetic condition. Patients should continue to follow their doctor’s treatment plan.
When will it be available in India?
CDSCO has granted marketing authorisation, which clears the regulatory path. Commercial availability and pricing details are yet to be announced by the company.
Wednesday’s approval is the kind of news that rarely makes front pages but changes lives quietly. The challenge now is making sure the promise reaches beyond the big metros.
